A Phase 1 interventional study of Insulin aspart and Recombinant human hyaluronidase PH20 (rHuPH20) in Type 1 Diabetes Mellitus, sponsored by Halozyme Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-25.
Sponsored by Halozyme Therapeutics · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.
Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 582nd largest by enrollment of the 1,242 interventional ones that give a count, is one of 47 that started in 2011, is one of 147 in phase 1, and was the 362nd registered.
3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 31–75 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 5–40
Wayne State University · Sites in United States
Ages 16–20
Medtronic MiniMed, Inc. · Sites in United States
Ages 2–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,458 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 206 · Phase 2 267 · Phase 3 167 · Phase 4 74
First in 1983; this study’s year is marked. 47 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 40 across the 1,242 interventional studies, 64 across the 203 observational. Of the 1,117 that completed or were terminated, 563 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
398 of 1,458 have an industry lead sponsor. The 10 most frequent:
Halozyme Therapeutics is the lead sponsor of 33 studies on the registry; 1 is open to participants now.
Halozyme Therapeutics has 7 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
117 of the studies in Diabetes Mellitus, Type 1 with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07076199Phase 3Novo Nordisk A/SA Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | 2027-01-25 |
| NCT06334133Phase 3vTv TherapeuticsCadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | 2027-04 |
| NCT07056699Phase 3The University of Texas Health Science Center at San AntonioSGLT2i, Pioglitazone, and Ketone Production in T1D | 2027-06-01 |
Add all 117 to your calendar (.ics) → With an account.
Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if recombinant human hyaluronidase PH20 (rHuPH20) will change the exposure and action of approved insulin analogs when given by continuous subcutaneous insulin infusion (CSII) in participants with Type 1 diabetes mellitus (T1DM).
This study is divided into Stage 1, 2, and 3. Stage 3 was started chronologically before Stage 2 and, prior to performing Stage 2, the Sponsor made the decision to terminate Stage 2. Stage 2 was not initiated due to a strategic business decision and termination was not based on safety or efficacy concerns. No participants were enrolled in Stage 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants first received 0.15 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 4 days (Days 1-4; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2 and 4. After a 5- to 14-day washout period, participants received 0.15 U/kg insulin aspart and 5 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (insulin aspart-rHuPH20) coadministered as a CSII, for 4 days (Days 5-8; Period 2), including during a 6-hr euglycemic clamp on Days 6 and 8.
Drug: Insulin aspart · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)
Participants first received 0.15 units per kilogram (U/kg) insulin aspart and 5 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (insulin aspart-rHuPH20) coadministered as a continuous subcutaneous insulin infusion (CSII), for 4 days (Days 1-4; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2 and 4. After a 5- to 14-day washout period, participants received 0.15 U/kg insulin aspart alone as a CSII, for 4 days (Days 5-8; Period 2), including during a 6-hr euglycemic clamp on Days 6 and 8.
Drug: Insulin aspart · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)
Participants first received 0.12 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 5 days (Days 1-5; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2, 3, and 5. On Day 2 only, a sham injection was administered 2.5 hr prior to the 6-hr euglycemic clamp. After a 5- to 14-day washout period, participants received 0.12 U/kg insulin aspart administered as a CSII, for 5 days (Days 6-10; Period 2), including during a 6-hr euglycemic clamp on Days 7, 8, and 10. On Day 7 only, a 1.0-milliliter (mL) subcutaneous (SC) injection of 1.25 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) was administered 2.5 hr prior to the 6-hr euglycemic clamp.
Drug: Insulin aspart · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)
Participants first received 0.12 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 5 days (Days 1-5; Period 1), including during a 6- hour (hr) euglycemic clamp on Days 2, 3, and 5. On Day 2 only, a 1.0-milliliter (mL) subcutaneous (SC) injection of 1.25 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) was administered 2.5 hr prior to the euglycemic clamp . After a 5- to 14- day washout period, participants received 0.12 U/kg insulin aspart administered as a CSII, for 5 days (Days 6-10; Period 2), including during a 6-hr euglycemic clamp on Days 7, 8, and 10. On Day 7 only, a sham injection was administered 2.5 hr prior to the 6-hour euglycemic clamp.
Drug: Insulin aspart · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)
Also known as: Novolog
Also known as: PH20, Hylenex
Early Insulin Exposure (%AUC[0-60]), Stage 1
Early insulin exposure, defined as the percentage of total insulin exposure (area under the insulin concentration curve \[AUC{0-360}\]) that occurs within the first hour following bolus dose of insulin during the 2 euglycemic clamps is presented. Blood samples were collected 10 minutes predose and at 0, 5, 10, 15, 20, 30, 45, 60, 120, 150, 180, 240, 300, and 360 minutes postdose during the euglycemic clamp.
Time frame: 10 minutes predose up to 60 minutes postdose
Early Exposure to Insulin (%AUC[0-60]), Stage 3
Early insulin exposure, defined as the percentage of total insulin exposure (area under the insulin concentration curve \[AUC{0-360}) that occurs within the first hour following bolus dose of insulin during the 2 euglycemic clamps is presented. Blood samples were collected 10 minutes predose and at 0, 5, 10, 15, 20, 30, 45, 60, 120, 150, 180, 240, 300, and 360 minutes postdose during the euglycemic clamp.
Time frame: 10 minutes predose up to 60 minutes postdose on Days 2/7, 3/8, and 5/10
Maximum Glucose Infusion Rate (GIRmax), Stage 1
Maximum glucose infusion rates (GIRmax) for Stage1 are presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
Time frame: 0 up to 360 minutes postdose on Day 2/6 and Day 4/8
Maximum Glucose Infusion Rate (GIRmax), Stage 3
Maximum glucose infusion rates (GIRmax) for Stage 3 are presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
Time frame: 0 up to 360 minutes postdose on Days 2/7, 3/8, and 5/10
Time to First Occurrence of Maximum Glucose Infusion Rate (tGIRmax), Stage 1
Time to first occurrence of maximum glucose infusion rate (tGIRmax) for Stage 1 is presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
Time frame: 0 up to 360 minutes postdose on Day 2/6 and Day 4/8
Time to First Occurrence of Maximum Glucose Infusion Rate (tGIRmax), Stage 3
Time to first occurrence of maximum glucose infusion rate (tGIRmax) for Stage 3 is presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
Time frame: 0 up to 360 minutes postdose on Days 2/7, 3/8, and 5/10
Time to 50% Maximum Glucose Infusion Rate (tGIR50%Max), Stage 1
Early and late times to 50% maximum glucose infusion rate (tGIR50%max) for Stage 1 are presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
Time frame: 0 up to 360 minutes postdose on day 2/6 and Day 4/8
Time to 50% Maximum Glucose Infusion Rate (tGIR50%Max), Stage 3
Early and late time to 50% maximum glucose infusion rates (tGIR50%max) for Stage 3 studies are presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
Time frame: 0 up to 360 minutes postdose on Days 2/7, 3/8, and 5/10
Time to 50% Total Glucose Infused (50%Gtot), Stage 1
Time to 50% total glucose infused (50%Gtot) is presented for Stage 1. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
Time frame: 0 up to 360 minutes postdose on Day 2/6 and Day 4/8
Time to 50% Total Glucose Infused (50%Gtot), Stage 3
Time to 50% of total glucose infused (50%Gtot) is presented for Stage 3. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
Time frame: 0 up to 360 minutes postdose on Days 2/7, 3/8, and 5/10
Area Under the Glucose Concentration Curve (AUC[0-360]), Stage 1
Area under the glucose concentration curve for 0 to 360 minutes (AUC\[0-360\]) from Stage 1 is presented. Blood samples were collected 30 and 10 minutes prior to insulin bolus and at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
Time frame: 30 minutes predose up to 360 minutes postdose on Day 2/6 and Day 4/8
Area Under the Glucose Concentration Curve (AUC[0-360]), Stage 3
Area under the glucose concentration curve from 0 to 360 minutes (AUC\[0-360\]) for Stage 3 studies is presented. Blood samples were collected 30 and 10 minutes prior to insulin bolus and at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
Time frame: 30 minutes predose up to 360 minutes postdose Days 2/7, 3/8, and 5/10
Duration of Insulin Action (AUMC[0-360]/AUC[0-360]), Stage 1
Duration of insulin action was calculated by dividing the area under the first moment curve (AUMC\[0-360\]) by the area under the concentration versus time curve (AUC\[0-360\]) for Stage 1. Blood samples were collected 10 minutes predose and at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
Time frame: 10 minutes predose up to 360 minutes postdose on Day 2/6 and Day 4/8
Duration of Insulin Action (AUMC[0-360]/AUC[0-360]), Stage 3
Duration of insulin action was calculated by dividing the area under the first moment curve (AUMC\[0-360\]) by the area under the concentration versus time curve (AUC\[0-360\]) for Stage 3. Blood samples were collected 10 minutes predose and at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
Time frame: 10 minutes predose up to 360 minutes postdose on Days 2/7, 3/8, and 5/10
| Milestone | Stage 1: Insulin Aspart First, Then Insulin Aspart-rHuPH20 | Stage 1: Insulin Aspart-rHuPH20 First, Then Insulin Aspart | Stage 3: Insulin Aspart First, Then Insulin Aspart + rHuPH20 | Stage 3: Insulin Aspart + rHuPH20 First, Then Insulin Aspart |
|---|---|---|---|---|
| Started | 11 | 9 | 13 | 12 |
| Received at least one dose of study drug | 11 | 9 | 13 | 12 |
| Completed | 9 | 9 | 10 | 10 |
| Not completed | 2 | 0 | 3 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 | 3 | 2 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Milestone | Stage 1: Insulin Aspart First, Then Insulin Aspart-rHuPH20 | Stage 1: Insulin Aspart-rHuPH20 First, Then Insulin Aspart | Stage 3: Insulin Aspart First, Then Insulin Aspart + rHuPH20 | Stage 3: Insulin Aspart + rHuPH20 First, Then Insulin Aspart |
|---|---|---|---|---|
| Started | 9 | 9 | 10 | 10 |
| Completed | 9 | 9 | 10 | 10 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Stage 1: Insulin Aspart First, Then Insulin Aspart-rHuPH20 | Stage 1: Insulin Aspart-rHuPH20 First, Then Insulin Aspart | Stage 3: Insulin Aspart First, Then Insulin Aspart + rHuPH20 | Stage 3: Insulin Aspart + rHuPH20 First, Then Insulin Aspart |
|---|---|---|---|---|
| Started | 9 | 9 | 10 | 10 |
| Completed | 8 | 8 | 9 | 8 |
| Not completed | 1 | 1 | 1 | 2 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 2 |
Early insulin exposure, defined as the percentage of total insulin exposure (area under the insulin concentration curve \[AUC{0-360}\]) that occurs within the first hour following bolus dose of insulin during the 2 euglycemic clamps is presented. Blood samples were collected 10 minutes predose and at 0, 5, 10, 15, 20, 30, 45, 60, 120, 150, 180, 240, 300, and 360 minutes postdose during the euglycemic clamp.
| Percentage of AUC(0-360) | Stage 1: Insulin Aspart Alone | Stage 1: Insulin Aspart-rHuPH20 |
|---|---|---|
| Stage 1, Day 2/6 | 20.99 ± 6.37 | 34.94 ± 9.48 |
| Stage 1, Day 4/8 | 32.83 ± 14.66 | 50.97 ± 13.91 |
Maximum glucose infusion rates (GIRmax) for Stage1 are presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
| Milligrams/kilogram/minute | Stage 1: Insulin Aspart Alone | Stage 1: Insulin Aspart-rHuPH20 |
|---|---|---|
| Stage 1, Day 2/6 | 13.37 ± 4.23 | 12.51 ± 3.19 |
| Stage 1, Day 4/8 | 11.88 ± 3.64 | 11.52 ± 3.67 |
Early insulin exposure, defined as the percentage of total insulin exposure (area under the insulin concentration curve \[AUC{0-360}) that occurs within the first hour following bolus dose of insulin during the 2 euglycemic clamps is presented. Blood samples were collected 10 minutes predose and at 0, 5, 10, 15, 20, 30, 45, 60, 120, 150, 180, 240, 300, and 360 minutes postdose during the euglycemic clamp.
| Percentage of AUC(0-360) | Stage 3: Insulin Aspart Alone | Stage 3: Insulin Aspart + rHuPH20 |
|---|---|---|
| Stage 3, Day 2/7 | 15.70 ± 6.38 | 32.11 ± 10.91 |
| Stage 3, Day 3/8 | 22.29 ± 5.43 | 36.39 ± 9.43 |
| Stage 3, Day 5/10 | 27.31 ± 10.49 | 32.64 ± 11.32 |
Maximum glucose infusion rates (GIRmax) for Stage 3 are presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
| Milligrams/kilogram/minute | Stage 3: Insulin Aspart Alone | Stage 3: Insulin Aspart + rHuPH20 |
|---|---|---|
| Stage 3, Day 2/7 | 9.58 ± 2.28 | 12.63 ± 3.88 |
| Stage 3, Day 3/8 | 10.07 ± 3.36 | 12.4 ± 3.39 |
| Stage 3, Day 5/10 | 9.97 ± 3.53 | 10.76 ± 3.35 |
Time to first occurrence of maximum glucose infusion rate (tGIRmax) for Stage 1 is presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
| Minutes | Stage 1: Insulin Aspart Alone | Stage 1: Insulin Aspart-rHuPH20 |
|---|---|---|
| Stage 1, Day 2/6 | 115.38 ± 59.21 | 102.38 ± 38.28 |
| Stage 1, Day 4/8 | 92.50 ± 24.71 | 84.31 ± 25.89 |
Time to first occurrence of maximum glucose infusion rate (tGIRmax) for Stage 3 is presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
| Minutes | Stage 3: Insulin Aspart Alone | Stage 3: Insulin Aspart + rHuPH20 |
|---|---|---|
| Stage 3, Day 2/7 | 127.65 ± 60.02 | 78.53 ± 27.04 |
| Stage 3, Day 3/8 | 135.24 ± 73.00 | 79.47 ± 42.57 |
| Stage 3, Day 5/10 | 117.76 ± 75.20 | 79.53 ± 42.99 |
Early and late times to 50% maximum glucose infusion rate (tGIR50%max) for Stage 1 are presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
| Minutes | Stage 1: Insulin Aspart Alone | Stage 1: Insulin Aspart-rHuPH20 |
|---|---|---|
| Early tGIR50%max, Stage 1, Day 2/6 | 46.50 ± 18.08 | 34.88 ± 17.92 |
| Late tGIR50%max, Stage 1, Day 2/6 | 162.19 ± 56.78 | 158.06 ± 52.58 |
| Early tGIR50%max, Stage 1, Day 4/8 | 35.19 ± 28.54 | 39.75 ± 18.71 |
| Late tGIR50%max, Stage 1, Day 4/8 | 132.63 ± 47.37 | 114.19 ± 29.05 |
Early and late time to 50% maximum glucose infusion rates (tGIR50%max) for Stage 3 studies are presented. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
| Minutes | Stage 3: Insulin Aspart Alone | Stage 3: Insulin Aspart + rHuPH20 |
|---|---|---|
| Early tGIR50%max, Stage 3, Day 2/7 | 58.47 ± 17.53 | 31.06 ± 20.73 |
| Late tGIR50%max, Stage 3, Day 2/7 | 144.18 ± 61.44 | 98.71 ± 39.87 |
| Early tGIR50%max, Stage 3, Day 3/8 | 32.59 ± 22.88 | 31.53 ± 21.27 |
| Late tGIR50%max, Stage 3, Day 3/8 | 153.41 ± 65.35 | 102.88 ± 44.57 |
| Early tGIR50%max, Stage 3, Day 5/10 | 27.29 ± 18.40 | 28.88 ± 21.97 |
| Late tGIR50%max, Stage 3, Day 5/10 | 136.88 ± 73.39 | 110.59 ± 55.10 |
Time to 50% total glucose infused (50%Gtot) is presented for Stage 1. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
| Minutes | Stage 1: Insulin Aspart Alone | Stage 1: Insulin Aspart-rHuPH20 |
|---|---|---|
| Stage 1, Day 2/6 | 156.13 ± 18.70 | 134.94 ± 18.28 |
| Stage 1, Day 4/8 | 137.38 ± 22.21 | 115.25 ± 14.50 |
Time to 50% of total glucose infused (50%Gtot) is presented for Stage 3. Blood samples were collected at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
| Minutes | Stage 3: Insulin Aspart Alone | Stage 3: Insulin Aspart + rHuPH20 |
|---|---|---|
| Stage 3, Day 2/7 | 174.59 ± 25.86 | 124.18 ± 22.03 |
| Stage 3, Day 3/8 | 154.06 ± 24.02 | 120.00 ± 17.12 |
| Stage 3, Day 5/10 | 146.59 ± 28.63 | 130.18 ± 23.54 |
Area under the glucose concentration curve for 0 to 360 minutes (AUC\[0-360\]) from Stage 1 is presented. Blood samples were collected 30 and 10 minutes prior to insulin bolus and at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
| Picomoles*minutes/liter | Stage 1: Insulin Aspart Alone | Stage 1: Insulin Aspart-rHuPH20 |
|---|---|---|
| Stage 1, Day 2/6 | 1978.08 ± 631.89 | 1977.02 ± 795.79 |
| Stage 1, Day 4/8 | 1598.40 ± 546.00 | 1324.31 ± 500.04 |
Area under the glucose concentration curve from 0 to 360 minutes (AUC\[0-360\]) for Stage 3 studies is presented. Blood samples were collected 30 and 10 minutes prior to insulin bolus and at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
| Picomoles*minutes/liter | Stage 3: Insulin Aspart Alone | Stage 3: Insulin Aspart + rHuPH20 |
|---|---|---|
| Stage 3, Day 2/7 | 1197.60 ± 385.44 | 1509.38 ± 541.45 |
| Stage 3, Day 3/8 | 1368.81 ± 424.16 | 1405.75 ± 516.85 |
| Stage 3, Day 5/10 | 1289.22 ± 486.03 | 1369.97 ± 462.78 |
Duration of insulin action was calculated by dividing the area under the first moment curve (AUMC\[0-360\]) by the area under the concentration versus time curve (AUC\[0-360\]) for Stage 1. Blood samples were collected 10 minutes predose and at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
| Ratio | Stage 1: Insulin Aspart Alone | Stage 1: Insulin Aspart-rHuPH20 |
|---|---|---|
| Stage 1, Day 2/6 | 163.63 ± 14.70 | 146.51 ± 16.30 |
| Stage 1, Day 4/8 | 147.50 ± 23.86 | 132.60 ± 15.55 |
Duration of insulin action was calculated by dividing the area under the first moment curve (AUMC\[0-360\]) by the area under the concentration versus time curve (AUC\[0-360\]) for Stage 3. Blood samples were collected 10 minutes predose and at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, and 360 minutes postdose during a euglycemic clamp.
| ratio | Stage 3: Insulin Aspart Alone | Stage 3: Insulin Aspart + rHuPH20 |
|---|---|---|
| Stage 3, Day 2/7 | 180.39 ± 18.72 | 138.59 ± 18.41 |
| Stage 3, Day 3/8 | 164.65 ± 19.97 | 135.71 ± 17.30 |
| Stage 3, Day 5/10 | 156.14 ± 26.38 | 145.81 ± 16.42 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stage 1: Insulin Aspart | — | 0/20 (0%) | 16/20 (80%) |
| Stage 1: Insulin Aspart-rHuPH20 | — | 0/18 (0%) | 13/18 (72.2%) |
| Stage 3: Insulin Aspart | — | 0/23 (0%) | 14/23 (60.9%) |
| Stage 3: Insulin Aspart + rHuPH20 | — | 0/22 (0%) | 12/22 (54.5%) |
| Event | Stage 1: Insulin Aspart | Stage 1: Insulin Aspart-rHuPH20 | Stage 3: Insulin Aspart | Stage 3: Insulin Aspart + rHuPH20 |
|---|---|---|---|---|
| HeadacheNervous system disorders | 7/20 | 3/18 | 4/23 | 3/22 |
| Incision site haemorrhageInjury, poisoning and procedural complications | 3/20 | 3/18 | 0/23 | 0/22 |
| Injection site erythemaGeneral disorders | 2/20 | 2/18 | 0/23 | 0/22 |
| Infusion site painGeneral disorders | 0/20 | 2/18 | 1/23 | 1/22 |
| Injection site haemorrhageGeneral disorders | 0/20 | 2/18 | 0/23 | 1/22 |
| Injection site pruritusGeneral disorders | 2/20 | 0/18 | 0/23 | 0/22 |
| Infusion site haematomaGeneral disorders | 2/20 | 1/18 | 0/23 | 1/22 |
| Infusion site extravasationGeneral disorders | 0/20 | 1/18 | 0/23 | 2/22 |
| NauseaGastrointestinal disorders | 1/20 | 1/18 | 0/23 | 2/22 |
| AnaemiaBlood and lymphatic system disorders | 0/20 | 1/18 | 0/23 | 2/22 |
All participants who received at least one dose of study drug.
| Age, Continuous(Years) | Stage 1: Insulin Aspart First, Then Insulin Aspart-rHuPH20 | Stage 1: Insulin Aspart-rHuPH20 First, Then Insulin Aspart | Stage 3: Insulin Aspart First, Then Insulin Aspart + rHuPH20 | Stage 3: Insulin Aspart + rHuPH20 First, Then Insulin Aspart | Total |
|---|---|---|---|---|---|
| Mean | 31.3 ± 6.39 | 44.6 ± 9.00 | 35.5 ± 9.50 | 32.3 ± 10.29 | 35.44 ± 9.95 |
| Sex: Female, Male(Participants) | Stage 1: Insulin Aspart First, Then Insulin Aspart-rHuPH20 | Stage 1: Insulin Aspart-rHuPH20 First, Then Insulin Aspart | Stage 3: Insulin Aspart First, Then Insulin Aspart + rHuPH20 | Stage 3: Insulin Aspart + rHuPH20 First, Then Insulin Aspart | Total |
|---|---|---|---|---|---|
| Female | 6 | 3 | 7 | 6 | 22 |
| Male | 5 | 6 | 6 | 6 | 23 |
| Race (NIH/OMB)(Participants) | Stage 1: Insulin Aspart First, Then Insulin Aspart-rHuPH20 | Stage 1: Insulin Aspart-rHuPH20 First, Then Insulin Aspart | Stage 3: Insulin Aspart First, Then Insulin Aspart + rHuPH20 | Stage 3: Insulin Aspart + rHuPH20 First, Then Insulin Aspart | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 | 2 |
| White | 11 | 9 | 11 | 11 | 42 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Stage 1: Insulin Aspart First, Then Insulin Aspart-rHuPH20 | Stage 1: Insulin Aspart-rHuPH20 First, Then Insulin Aspart | Stage 3: Insulin Aspart First, Then Insulin Aspart + rHuPH20 | Stage 3: Insulin Aspart + rHuPH20 First, Then Insulin Aspart | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 0 | 0 | 2 |
| Not Hispanic or Latino | 10 | 8 | 13 | 12 | 43 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Stage 1: Insulin Aspart First, Then Insulin Aspart-rHuPH20 | Stage 1: Insulin Aspart-rHuPH20 First, Then Insulin Aspart | Stage 3: Insulin Aspart First, Then Insulin Aspart + rHuPH20 | Stage 3: Insulin Aspart + rHuPH20 First, Then Insulin Aspart | Total |
|---|---|---|---|---|---|
| United States | 11 | 9 | 13 | 12 | 45 |
The record gives a start of Jan 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hyaluronidase (human recombinant)